Posters and Presentations

Saturday, June 4, 2016

Poster Session: Gastrointestinal (Colorectal) Cancer

Tumor mutational burden as a potential biomarker for PD1/PD-L1 therapy in colorectal cancer


Time: 8–11:30am CDT
Location: Hall A

+ show details
 

Poster Session: Gastrointestinal (Colorectal) Cancer

Emerging genomic landscape and therapeutic targets in young patients with colorectal cancer (CRC)


Time: 8–11:30am CDT
Location: Hall A

+ show details
 

Poster Session: Gastrointestinal (Colorectal) Cancer

Genomic distinctions between colon and rectal cancer in young patients


Time: 8–11:30am CDT
Location: Hall A

+ show details
 

Poster Session: Gastrointestinal (Noncolorectal) Cancer

Genomic profiling to distinguish poorly differentiated neuroendocrine carcinomas arising in different sites


Time: 8–11:30am CDT
Location: Hall A

+ show details
 

Poster Session: Lung Cancer—Non-Small Cell Metastatic

Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies


Time: 8–11:30am CDT
Location: Hall A

+ show details
 

Poster Session: Lung Cancer—Non-Small Cell Metastatic

Comprehensive genomic profiling of 298 lung cancers of varying histologies harboring MET exon 14 alterations


Time: 8–11:30am CDT
Location: Hall A

+ show details
 

Poster Session: Lung Cancer—Non-Small Cell Metastatic

MDM2 amplification (Amp) to mediate cabozantinib resistance in patients (Pts) with advanced RET-rearranged lung cancers


Time: 8–11:30am CDT
Location: Hall A

+ show details
 

Poster Session: Lung Cancer—Non-Small Cell Metastatic

Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion


Time: 8–11:30am CDT
Location: Hall A

+ show details
 

Poster Session: Lung Cancer—Non-Small Cell Metastatic

The Genomics of Young Lung Cancer (GYLC)


Time: 8–11:30am CDT
Location: Hall A

+ show details
 

Poster Session: Lung Cancer—Non-Small Cell Metastatic

Lung-MAP (S1400) Lung Cancer Master Protocol: Accrual, demographics, and molecular markers


Time: 8–11:30am CDT
Location: Hall A

+ show details
 

Poster Session: Melanoma/Skin Cancers

Analysis of tumor mutation burden (TMB) in >51,000 clinical cancer patients to identify novel non-coding PMS2 promoter mutations associated with increased TMB


Time: 1–4:30pm CDT
Location: Hall A

+ show details
 

Poster Session: Melanoma/Skin Cancers

Deep sequencing of metastatic cutaneous basal cell and squamous cell carcinomas to reveal distinctive genomic profiles and new routes to targeted therapies


Time: 1–4:30pm CDT
Location: Hall A

+ show details
 

Poster Session: Genitourinary (Prostate) Cancer

Comprehensive Genomic Profiling of Neuroendocrine Carcinoma of the Prostate


Time: 1:00–4:30pm CDT
Location: Hall A

+ show details
 

Poster Session: Genitourinary (Prostate) Cancer

TMPRSS-ERG fusion in men with prostate cancer (PCa) and non-prostate malignancies: Defining a role for comprehensive genomic profiling (CGP) to guide clinical care


Time: 1:00–4:30pm CDT
Location: Hall A

+ show details
 

Poster Session: Head and Neck Cancer

Comprehensive Genomic sequencing (CGS) of 90 patient samples of anaplastic thyroid cancer (ATC)


Poster Session Time:
1–4:30pm CDT
Poster Session Location: Hall A
Poster Discussion Time:
4:45–6pm CDT
Poster Discussion Location: S406

+ show details
Sunday, June 5, 2016

Poster Session: Developmental Therapeutics—Immunotherapy

Biomarkers of immune checkpoint inhibitor response in metastatic breast cancer: PD-L1 protein expression, CD274 gene amplification, and total mutational burden.


Time: 8–11:30am CDT
Location: Hall A

+ show details
 

Clinical Science Symposium: Immunotherapy: Now We’re Getting Personal – Using Genomics and Biomarkers to Predict Response

PD-L1 expression, Cancer Genome Atlas (TCGA) subtype, and mutational load as independent predictors of response to atezolizumab (atezo) in metastatic urothelial carcinoma (mUC; IMvigor210)


Time: 9:57–10:09am CDT
Location: Hall D1

+ show details
 

Clinical Science Symposium: Immunotherapy: Now We’re Getting Personal – Using Genomics and Biomarkers to Predict Response

Hybrid capture-based next-generation sequencing (HC NGS) in melanoma to identify markers of response to anti-PD-1/PD-L1


Time: 10:21–10:33am CDT
Location: Hall D1

+ show details
Monday, June 6, 2016

Poster Discussion: Cancer Prevention, Genetics, and Epidemiology

Evaluation of microsatellite instability (MSI) status in 11,573 diverse solid tumors using comprehensive genomic profiling (CGP)


Poster Session Time:
8–11:30am CDT
Poster Session Location: Hall A
Poster Discussion Time:
1:15–2:30pm CDT
Poster Discussion Location: S404

+ show details
 

Poster Session: Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Distinct age-associated genomic profiles in acute myeloid leukemia (AML) using FoundationOne Heme


Time: 8–11:30am CDT
Location: Hall A

+ show details
 

Poster Session: Tumor Biology

DNA-based genomic profiling for classification of tissue of origin for patients with carcinoma of unknown primary site


Poster Session Time:
1–4:30pm CDT
Poster Session Location: Hall A
Poster Discussion Time:
4:45–6:00pm CDT
Poster Discussion Location: S406

+ show details
 

Poster Session: Tumor Biology

Decision impact analysis of comprehensive genomic profiling (CGP) in advanced breast cancer: A prospective study


Time: 1–4:30pm CDT
Location: Hall A

+ show details
 

Poster Session: Tumor Biology

Assessment of tumor mutation burden from >60,000 clinical cancer patients using comprehensive genomic profiling


Time: 1–4:30pm CDT
Location: Hall A

+ show details
 

Poster Session: Tumor Biology

Investigating the Utility of comprehensive genomic Profiling for patients with newly diagnosed breast cancer


Time: 1–4:30pm CDT
Location: Hall A

+ show details
 

Poster Session: Genitourinary (Nonprostate) Cancer

Comprehensive genomic profiling to identify clinically relevant genomic alterations in patients with advanced penile cancers


Time: 1–4:30pm CDT
Location: Hall A

+ show details
 

Poster Session: Gynecologic Cancer

Immunotherapy (IO) versus targeted therapy triage in endometrial adenocarcinoma (EA) by concurrent assessment of tumor mutation burden (TMB), microsatellite instability (MSI) status, and targetable genomic alterations (GA)


Time: 1–4:30pm CDT
Location: Hall A

+ show details
 

Poster Session: Genitourinary (Nonprostate) Cancer

Comparison of upper tract urothelial carcinoma and urothelial carcinoma of the bladder to reveal key differences in mutational profile and load


Time: 1–4:30pm CDT
Location: Hall A

+ show details
 

We would love to see you in Chicago!

Here are some of the places you will
Find us during the 2016 ASCO Annual Meeting

 

Visit us at McCormick Convention Center
BOOTH #24109

Join us for an engaging panel dinner on
Thursday, June 2nd at 6:30pm
 

 

SCHEDULE A MEETING
WITH OUR TEAM

at our booth


Schedule 1-on-1s with our
SENIOR LEADERSHIP
AND SCIENTISTS



Celebrate a great year with us
at the Chicago Illuminating Company
SUNDAY, JUNE 5TH